Eli Lilly and Company (LLY)

Basic

  • Market Cap

    $537.83B

  • EV

    $555.09B

  • Shares Out

    899.31M

  • Revenue

    $32.07B

  • Employees

    39,000

Margins

  • Gross

    78.67%

  • EBITDA

    35.28%

  • Operating

    30.56%

  • Pre-Tax

    19.15%

  • Net

    15.55%

  • FCF

    8.84%

Returns (5Yr Avg)

  • ROA

    9.96%

  • ROE

    86.68%

  • ROCE

    22.68%

  • ROIC

    19.33%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $619.14

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $35.61

  • Earnings (Dil)

    $5.52

  • FCF

    $3.14

  • Book Value

    $12.48

Growth (CAGR)

  • Rev 3Yr

    11.38%

  • Rev 5Yr

    7.81%

  • Rev 10Yr

    3.26%

  • Dil EPS 3Yr

    -3.33%

  • Dil EPS 5Yr

    72.7%

  • Dil EPS 10Yr

    2.37%

  • Rev Fwd 2Yr

    16.65%

  • EBITDA Fwd 2Yr

    23.85%

  • EPS Fwd 2Yr

    24.5%

  • EPS LT Growth Est

    21.24%

Dividends

  • Yield

    —

  • Payout

    78.89%

  • DPS

    $4.37

  • DPS Growth 3Yr

    15.11%

  • DPS Growth 5Yr

    14.63%

  • DPS Growth 10Yr

    8.35%

  • DPS Growth Fwd 2Yr

    14.67%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

21,493.3

22,319.5

24,539.8

28,318.4

28,541.4

32,072.5

Total Revenues % Chg.

7.6%

3.8%

9.9%

15.4%

0.8%

9.7%

Cost of Goods Sold, Total

4,681.7

4,721.2

5,483.3

6,973.1

6,629.8

6,842.3

Gross Profit

16,811.6

17,598.3

19,056.5

21,345.3

21,911.6

25,230.2

Selling General & Admin Expenses, Total

5,734.6

6,003.9

5,869.4

6,141.9

6,067.5

6,681.9

R&D Expenses

5,051.2

5,595.0

5,976.3

6,930.7

7,190.8

8,746.6

Other Operating Expenses, Total

10,785.8

11,598.9

11,845.7

13,072.6

13,258.3

15,428.5

Operating Income

6,025.8

5,999.4

7,210.8

8,272.7

8,653.3

9,801.7

Interest Expense, Total

-242.5

-400.6

-359.6

-339.8

-331.6

-431.7

Interest And Investment Income

159.3

80.4

33.0

25.4

62.8

154.6

Net Interest Expenses

-83.2

-320.2

-326.6

-314.4

-268.8

-277.1

Currency Exchange Gains (Loss)

-100.0

-61.9

123.7

-204.6

-191.3

-88.4

Other Non Operating Income (Expenses)

88.3

5.3

-319.2

256.0

177.0

46.0

EBT, Excl. Unusual Items

5,930.9

5,622.6

6,688.7

8,009.7

8,370.2

9,482.2

Restructuring Charges

-127.8

-77.8

-151.2

-13.0

-23.0

-23.0

Merger & Related Restructuring Charges

—

-400.7

—

—

—

—

Gain (Loss) On Sale Of Investments

—

401.2

1,442.2

176.9

-410.7

115.4

Gain (Loss) On Sale Of Assets

—

309.8

—

—

—

—

Asset Writedown

—

—

—

—

—

206.5

In Process R&D Expenses

-1,983.9

-239.6

-769.8

-970.1

-908.5

-3,417.3

Other Unusual Items

-139.1

-349.6

20.0

-1,048.0

-221.6

-221.6

EBT, Incl. Unusual Items

3,680.1

5,265.9

7,229.9

6,155.5

6,806.4

6,142.2

Income Tax Expense

529.5

628.0

1,036.2

573.8

561.6

1,153.8

Earnings From Continuing Operations

3,150.6

4,637.9

6,193.7

5,581.7

6,244.8

4,988.4

Earnings Of Discontinued Operations

81.4

3,680.5

—

—

—

—

Net Income

3,232.0

8,318.4

6,193.7

5,581.7

6,244.8

4,988.4

Net Income to Common Incl Extra Items

3,232.0

8,318.4

6,193.7

5,581.7

6,244.8

4,988.4

Net Income to Common Excl. Extra Items

3,150.6

4,637.9

6,193.7

5,581.7

6,244.8

4,988.4

Total Shares Outstanding

1,007.0

907.5

906.6

903.7

900.2

899.3

Weighted Avg. Shares Outstanding

1,027.7

931.1

907.6

907.0

901.7

900.5

Weighted Avg. Shares Outstanding Dil

1,033.7

935.7

912.5

911.7

904.6

903.6

EPS

3.1

8.9

6.8

6.2

6.9

5.5

EPS Diluted

3.1

8.9

6.8

6.1

6.9

5.5

EBITDA

7,634.8

7,232.0

8,534.7

9,820.3

10,175.8

11,316.3